Target Trial Emulation of Second-Generation Versus First-Generation Tyrosine Kinase Inhibitors in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
文献摘要
Purpose Philadelphia chromosome-positive acute lymphoblastic leukemia accounts for approximately 20%-30% of adult acute lymphoblastic leukemia and remains associated with relapse despite imatinib-based therapy. We compared the effectiveness and safety of first-generation versus second-generation tyrosine kinase inhibitors (TKIs) in adults with newly diagnosed disease. Methods We conducted a retrospective target trial emulation using TriNetX electronic health record data from January 2014 to February 2025. Adults age 18 years or older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia were eligible. After exclusions, 2,764 patients were clinically eligible; 2,295 met the as-started exposure definition for the primary comparison. Propensity score matching yielded 592 patients per arm comparing imatinib with second-generation TKIs, predominantly dasatinib. Results At a median follow-up of 1,140 days for the second-generation cohort versus 1,129 days for imatinib, second-generation TKIs were associated with improved overall survival (hazard ratio, 0.677 [95% CI, 0.544 to 0.842]; P v 38.7%; risk ratio, 0.681 [95% CI, 0.576 to 0.806; P Conclusion Second-generation TKIs, particularly dasatinib, may be considered as frontline therapy for many adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, particularly those younger than 65 years.